A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

This trial compares a biosimilar version of nivolumab (LY01015) against the original nivolumab (Opdivo), each combined with chemotherapy, as a first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (a type of esophageal cancer) to confirm they work equally well. **You may be eligible if...** - You are between 18 and 75 with confirmed esophageal squamous cell carcinoma that is advanced or has spread - You have not previously received systemic cancer treatment for metastatic disease - Your tumor tests positive for PD-L1 (TPS 1% or higher) - You are in good physical health (ECOG 0–1) with adequate organ function - You have at least one measurable tumor **You may NOT be eligible if...** - You have symptomatic brain metastases or leptomeningeal disease - Your tumor severely blocks the esophagus or invades nearby organs with high bleeding or fistula risk - You have had prior anti-PD-1/PD-L1 or checkpoint immunotherapy - You have had unstable heart disease, stroke, or severe arrhythmia in the past 6 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.